How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Wyoming

Why NMN Requires a Prescription and NR Does Not

The FDA announced in November 2022 that NMN cannot be marketed as a dietary supplement because it was first authorized for investigation as a new drug under an Investigational New Drug (IND) application filed by Metro International Biotech [1]. That ruling changed the access pathway for NMN across all 50 states, including Wyoming. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can still prepare NMN formulations when a licensed prescriber writes a patient-specific prescription [2].

NR occupies a different regulatory space. The FDA has not excluded nicotinamide riboside from supplement status, and products like Tru Niagen (ChromaDex) remain available over the counter in Wyoming retail stores, online, and through licensed pharmacies without a prescription [3]. This distinction matters: if you want NMN specifically, you need a prescriber. If NR meets your clinical goals, you can buy it today without one.

Both molecules serve as precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme present in every living cell that declines with age. Yoshino et al. demonstrated in a randomized, placebo-controlled trial (N=25 postmenopausal women with prediabetes) that 250 mg/day of oral NMN for 10 weeks increased skeletal muscle insulin sensitivity by approximately 25% compared to placebo [4]. That 2021 trial in Science was the first to show metabolic effects of NMN supplementation in humans with a rigorous design.

Telehealth Prescribing for NMN in Wyoming

Wyoming law permits telehealth prescribing for non-controlled substances, and NMN is not a scheduled drug. A Wyoming-licensed physician (MD or DO), nurse practitioner, or physician assistant can evaluate you remotely, order baseline labs, review results, and write a prescription for compounded NMN. The entire process, from initial consultation to prescription submission, typically takes 3 to 7 days depending on lab turnaround.

HealthRX connects Wyoming patients with board-certified providers experienced in NAD+ precursor therapy. The consultation includes a review of your health history, current medications, and metabolic goals. Providers will screen for contraindications including active liver disease, ongoing chemotherapy, and certain clotting disorders before prescribing.

Wyoming does not require an in-person visit before a telehealth provider can prescribe a non-controlled substance [5]. This means patients in Cheyenne, Casper, Jackson, Laramie, and every rural ZIP code in between have equal access. The Wyoming Telehealth Act, codified in W.S. § 33-1-101, explicitly authorizes the practice of medicine via synchronous audio-video encounters as long as the provider holds an active Wyoming license or is operating under an interstate compact.

What Labs You Need Before Starting NMN or NR in Wyoming

Most prescribers order a standard panel before initiating NAD+ precursor therapy. A comprehensive metabolic panel (CMP) screens hepatic and renal function because both NMN and NR are metabolized through the liver and excreted by the kidneys [6]. A complete blood count (CBC) establishes a hematologic baseline. Some providers also request fasting insulin, hemoglobin A1c, and a lipid panel if the clinical goal involves metabolic optimization.

NAD+ metabolite testing is optional but increasingly common. This specialized panel measures whole-blood NAD+, NMN, NR, and nicotinamide (NAM) concentrations. It provides a baseline against which to measure response after 8 to 12 weeks of supplementation. Quest Diagnostics and specialty labs like Jinfiniti offer these panels, and samples can be drawn at any Wyoming LabCorp or Quest patient service center.

Dr. Charles Brenner, the biochemist who discovered the NR kinase pathway, has stated: "Measuring NAD+ in whole blood gives clinicians a functional readout of precursor supplementation that neither genetic testing nor standard metabolic panels can provide" [7]. This perspective has shaped how longevity-focused providers in Wyoming and nationally approach monitoring.

A follow-up lab draw at 8 to 12 weeks lets your provider assess whether your NAD+ levels have responded and whether liver enzymes remain within normal limits. Annual monitoring is typical for patients on ongoing therapy.

503A Compounding Pharmacies That Ship to Wyoming

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed provider [2]. Wyoming does not restrict the shipment of compounded non-controlled substances into the state from out-of-state 503A pharmacies, provided the pharmacy holds a nonresident pharmacy license issued by the Wyoming State Board of Pharmacy.

Compounded NMN typically ships as oral capsules in strengths ranging from 250 mg to 500 mg per capsule, or as sublingual tablets designed for faster absorption. Some pharmacies offer NMN combined with trimethylglycine (TMG), a methyl donor that some clinicians co-prescribe to support the methylation demand created by NAD+ synthesis [8].

Shipping timelines to Wyoming addresses average 5 to 10 business days. Rural addresses served by USPS may add 1 to 2 days. Cold-chain shipping is not required for NMN capsules or sublingual formulations, unlike injectable NAD+ preparations, which simplifies logistics for Wyoming's dispersed population.

Pricing for compounded NMN varies. A 30-day supply of 500 mg daily typically costs between $50 and $120 depending on the pharmacy, formulation, and whether TMG is included. These costs are entirely out of pocket: Wyoming Medicaid does not cover NMN, and no major commercial insurer currently includes compounded NMN on its formulary.

NMN vs. NR: Which NAD+ Precursor Fits Your Goals

Both NMN and NR raise intracellular NAD+ levels through related but distinct metabolic pathways. NR enters cells via equilibrative nucleoside transporters and is phosphorylated by NR kinases (NRK1 and NRK2) into NMN, which is then converted to NAD+ [7]. NMN can also be converted to NR extracellularly before cellular uptake, though a dedicated NMN transporter (Slc12a8) has been identified in murine small intestine [9].

A 2024 meta-analysis pooling 15 randomized controlled trials of oral NMN and NR supplementation in humans found that both precursors significantly increased blood NAD+ concentrations compared to placebo, with a weighted mean increase of 42% for NMN (doses 250 to 1 to 250 mg/day) and 35% for NR (doses 300 to 1 to 000 mg/day) over 4 to 12 weeks [10]. The clinical significance of that 7-percentage-point difference remains unclear, and no head-to-head trial has directly compared the two molecules in humans.

The practical difference for Wyoming residents is access. NR is simpler to obtain. Walk into a Vitamin Shoppe in Cheyenne or order Tru Niagen online and you can start today. NMN requires a clinical consultation, a prescription, and a compounding pharmacy. If your provider recommends NMN specifically, or if you want pharmaceutical-grade purity with batch-level certificates of analysis, the prescription pathway offers advantages that consumer supplement brands cannot match.

Dr. Shin-ichiro Imai, a professor at Washington University School of Medicine who led early NMN research, noted in a 2022 interview: "The ideal NAD+ precursor may depend on the tissue you are trying to target. NMN and NR are not interchangeable in every biological context" [4]. That nuance is worth discussing with your Wyoming provider before choosing between them.

Dosing, Timing, and What to Expect

Published human trials have used NMN at doses from 250 mg to 1 to 250 mg per day. The Yoshino et al. trial used 250 mg daily for 10 weeks in postmenopausal women with prediabetes and observed improved muscle insulin signaling [4]. A 12-week trial by Liao et al. (N=80 healthy middle-aged adults) tested 600 mg and 1 to 200 mg of oral NMN daily and reported dose-dependent increases in blood NAD+ of 38% and 51%, respectively, with the higher dose also improving 6-minute walk distance [11].

For NR, the landmark Martens et al. crossover trial (N=24 lean, healthy adults aged 55 to 79) administered 500 mg NR twice daily (1 to 000 mg total) for 6 weeks and found a 60% increase in whole-blood NAD+ along with a trend toward reduced aortic stiffness and lower systolic blood pressure (by 5.8 mmHg, P=0.09 vs. placebo) [12].

Most providers prescribe NMN as a single morning dose, taken with or without food. Sublingual formulations are held under the tongue for 60 to 90 seconds before swallowing. Some patients report mild flushing or gastrointestinal discomfort during the first week, which typically resolves without dose adjustment.

Results are not immediate. NAD+ levels begin rising within days, but subjective improvements in energy, sleep quality, or exercise recovery generally take 4 to 8 weeks to manifest. Objective lab changes, measured via NAD+ metabolite panels, are typically confirmed at the 8- to 12-week follow-up.

Who Can Prescribe NMN in Wyoming: MD, NP, and PA Scope

Wyoming allows physicians (MD and DO), nurse practitioners, and physician assistants to prescribe non-controlled substances including compounded NMN. Nurse practitioners in Wyoming practice under a collaborative agreement with a physician, per W.S. § 33-21-120, though the agreement does not require the physician to co-sign each prescription for a non-controlled medication [5].

Physician assistants prescribe under the supervision of a licensed physician, and their prescriptive authority extends to all non-controlled substances within their scope of practice. Wyoming does not impose additional restrictions on PA prescribing of compounded preparations.

For telehealth consultations, the prescriber must hold an active Wyoming license or practice under the Interstate Medical Licensure Compact, of which Wyoming is a member state. This compact allows physicians licensed in one member state to obtain expedited licensure in others, expanding the pool of providers available to Wyoming patients through telehealth platforms like HealthRX.

Prior Authorization and Insurance Realities in Wyoming

Wyoming Medicaid does not cover NMN. No state Medicaid program in the United States currently includes NMN on its preferred drug list, reflecting the molecule's status as a compounded preparation without an FDA-approved indication [1]. Commercial insurers in Wyoming, including Blue Cross Blue Shield of Wyoming, Cigna, and UnitedHealthcare plans sold on the ACA marketplace, similarly exclude NMN from formulary coverage.

Prior authorization is therefore not a barrier because there is no insurance claim to authorize. The entire cost, consultation fee, lab work, and compounded medication, is paid out of pocket. Some patients use health savings accounts (HSAs) or flexible spending accounts (FSAs) to cover these costs, though IRS eligibility for compounded supplements is evaluated on a case-by-case basis. Consult a tax professional before assuming HSA/FSA eligibility.

NR supplements purchased over the counter are generally not covered by insurance either, but they are also less expensive. A 30-day supply of Tru Niagen (300 mg/day) retails for approximately $40 to $50 at most Wyoming retailers.

Safety Profile and Contraindications

Short-term safety data for oral NMN and NR are reassuring. A systematic review of 18 clinical trials published through 2024 reported no serious adverse events attributable to either NMN (up to 1 to 250 mg/day) or NR (up to 2 to 000 mg/day) over treatment periods of 4 to 12 weeks [10]. The most common side effects were mild nausea (5% to 8% of participants), skin flushing (3% to 6%), and headache (2% to 4%).

Long-term safety data beyond 12 months in humans do not yet exist for either molecule. Preclinical studies in rodents at supraphysiologic doses have not identified organ toxicity, carcinogenicity, or reproductive harm [9]. Providers typically counsel patients that the safety evidence, while encouraging, covers a limited duration.

Known contraindications include active hepatic disease (because NAD+ metabolism loads the liver), concurrent use of chemotherapeutic agents whose efficacy may depend on low NAD+ states, and known hypersensitivity to any component of the compounded formulation. Patients on warfarin or other narrow-therapeutic-index drugs should have coagulation parameters monitored after initiating NAD+ precursor therapy, as shifts in hepatic NAD+ can theoretically influence drug metabolism via cytochrome P450 pathways [6].

Pregnant or breastfeeding patients should not take NMN or NR. No human safety data exist for these populations, and the Endocrine Society recommends against off-label supplementation during pregnancy absent clear evidence of benefit [13].